KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Finished Goods (2016 - 2025)

Historic Finished Goods for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $16.7 million.

  • Supernus Pharmaceuticals' Finished Goods fell 3127.78% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 3127.78%. This contributed to the annual value of $16.4 million for FY2024, which is 4505.38% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Finished Goods stood at $16.7 million for Q3 2025, which was down 3127.78% from $20.0 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Finished Goods' 5-year high stood at $46.7 million during Q3 2022, with a 5-year trough of $12.5 million in Q3 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' median Finished Goods value was $29.9 million (recorded in 2023), while the average stood at $27.9 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Finished Goods surged by 27249.3% in 2022 and then tumbled by 4505.38% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Finished Goods stood at $32.9 million in 2021, then grew by 6.34% to $35.0 million in 2022, then dropped by 14.54% to $29.9 million in 2023, then plummeted by 45.05% to $16.4 million in 2024, then grew by 1.61% to $16.7 million in 2025.
  • Its last three reported values are $16.7 million in Q3 2025, $20.0 million for Q2 2025, and $22.1 million during Q1 2025.